Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.